Prostate cancer is thought to be immunologically “cold,” lacking in tumor infiltrating lymphocytes (TILs), thereby limiting the effectiveness of PD-1 blockade which favors high-TIL tumors (88). Here, PDCD1 is linked to prostate carcinoma.